Metabolic Research Peptides

This category covers the somatotropic-axis peptides that preceded semaglutide (GLP-1 receptor agonist), tirzepatide (dual GIP/GLP-1), retatrutide (triple GIP/GLP-1/glucagon), and the long-acting amylin analogue cagrilintide in energy-balance research.

Growth-hormone-axis compounds include sermorelin, the benchmark GHRH(1-29) fragment; CJC-1295 without DAC (Modified GRF 1-29); tesamorelin, the GHRH analogue with the deepest clinical evidence base; and ipamorelin, the selective ghrelin-receptor secretagogue. They are studied alone and in the classic CJC/ipamorelin combination for pulsatile GH release. The category also includes 5-Amino-1MQ, a small-molecule NNMT inhibitor studied for NAD+-linked adipocyte metabolism, and AOD-9604, the lipolytic hGH fragment.

Every product page carries per-batch purity data, spec tables with cost-per-milligram, and plain-English summaries of the key studies. For research use only — not for human or veterinary use.